In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Chlortalidone for peak identification, European Pharmacopoeia (EP) Reference Standard Drug Master File in Korea (Chlortalidone for peak identification, European Pharmacopoeia (EP) Reference Standard KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Chlortalidone for peak identification, European Pharmacopoeia (EP) Reference Standard. The MFDS reviews the Chlortalidone for peak identification, European Pharmacopoeia (EP) Reference Standard KDMF as part of the drug registration process and uses the information provided in the Chlortalidone for peak identification, European Pharmacopoeia (EP) Reference Standard KDMF to evaluate the safety and efficacy of the drug.
After submitting a Chlortalidone for peak identification, European Pharmacopoeia (EP) Reference Standard KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Chlortalidone for peak identification, European Pharmacopoeia (EP) Reference Standard API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Chlortalidone for peak identification, European Pharmacopoeia (EP) Reference Standard suppliers with KDMF on PharmaCompass.